Susceptibility testing of tigecycline against Acinetobacter spp. by disc diffusion method: withdrawing a therapeutic option by varying the Mueller-Hinton agar?

作者: L. F. Canigia , C. Bantar

DOI: 10.1093/JAC/DKN389

关键词:

摘要: 1. Tally FP, DeBruin MF. Development of daptomycin for Gram-positive infections. J Antimicrob Chemother 2000; 46: 523–6. 2. Rybak MJ, Bailey EM, Lamp KC et al. Pharmacokinetics and bactericidal rates vancomycin in intravenous drug abusers being treated endocarditis bacteraemia. Agents 1992; 36: 1109–14. 3. Tedesco KL, MJ. Daptomycin. Pharmacotherapy 2004; 24: 41–57. 4. Sauermann R, Rothenburger M, Graninger W Daptomycin: a review 4 years after first approval. Pharmacology 2008; 81: 79–91. 5. Benvenuto Benziger DP, Yankelev S tolerability at doses up to 12 milligrams per kilogram body weight once daily healthy volunteers. 2006; 50: 3245–9.

参考文章(4)
R. N. Jones, M. J. Ferraro, L. B. Reller, P. C. Schreckenberger, J. M. Swenson, H. S. Sader, Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp Journal of Clinical Microbiology. ,vol. 45, pp. 227- 230 ,(2007) , 10.1128/JCM.01588-06
V. Thamlikitkul, S. Tiengrim, Effect of different Mueller–Hinton agars on tigecycline disc diffusion susceptibility for Acinetobacter spp. Journal of Antimicrobial Chemotherapy. ,vol. 62, pp. 847- 848 ,(2008) , 10.1093/JAC/DKN267
Jason J Schafer, Debra A Goff, Kurt B Stevenson, Julie E Mangino, Early experience with tigecycline for ventilator-associated pneumonia and bacteremia caused by multidrug-resistant Acinetobacter baumannii. Pharmacotherapy. ,vol. 27, pp. 980- 987 ,(2007) , 10.1592/PHCO.27.7.980
Surapee Tiengrim, Chanwit Tribuddharat, Visanu Thamlikitkul, In vitro activity of tigecycline against clinical isolates of multidrug-resistant Acinetobacter baumannii in Siriraj Hospital, Thailand. Journal of the Medical Association of Thailand Chotmaihet thangphaet. ,(2006)